


By 2050, half the world's population, 5 billion people, could be myopic.²

Myopia is an eye condition in which people can see closer objects clearly, but objects farther away appear blurred.³

Today, myopia is becoming increasingly common in younger generations across the world.⁴



The younger a child becomes myopic the faster their myopia progresses.⁵




Extracted from reference number 5



Don't just correct myopia with single vision lenses. Choose to slow its progression.

The first FDA market authorized spectacle lens to slow myopia progression in children*¹


For over 45 years, Essilor® has been dedicated to improving myopia management solutions for children through continuous research and innovation



*Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 4-12 years at initiation of treatment.

How do the Essilor® Stellest® lenses work?

Whereas standard single vision lenses only correct myopia, Essilor® Stellest® lenses correct and can slow myopia progression:



Correct myopia with Single Vision Zone


The single vision zone, carrying the prescription of the wearer, provides sharp vision by perfectly focusing light on the retina.

The lens design ensures a large single vision zone, providing good vision and comfort.

Slow myopia progression in children,^{†1} with H.A.L.T.† Technology

H.A.L.T.† technology consists of 1021 highly aspherical lenslets, arranged over 11 rings of contiguous lenslets, covering 40% of the lens surface.

When light rays pass through these aspherical lenslets they create a volume of myopic defocus in front of the retina, which follows the shape of a child's theoretical myopic retina.[‡]



The volume of myopic defocus provides a myopia progression slow down signal.

- Essilor® Stellest® lenses slowed myopia progression by **71%** on average over 2 years*¹

*H.A.L.T. is an acronym for Highly Aspherical Lenslet Target and does not imply a "halt" or "stop" of myopia progression.
†Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6-12 years at initiation of treatment.
‡Aspheric lenslet.



Summary

MiSight® 1 day is a significant and differentiating advancement in myopia control for age-appropriate children, combining innovative design with clinically proven results with its ActivControl® Technology.^{†1} The unique lens design delivers clarity and comfort needed for active lifestyles while slowing the progression of myopia in the eyes.²⁷

Unique Design for Myopia Control



ActivControl® Technology is specifically designed to address one of the underlying causes of myopia progression in age-appropriate children.^{†1} It features a unique lens design that combines peripheral treatment zones with central distance correction zones. This innovative design helps slow eye elongation rates while correcting vision, allowing children to engage in their daily activities with clarity and comfort.^{†1}

FDA- Approved* Efficacy and Safety



MiSight® 1 day is the first and only FDA-approved* soft contact lens proven to slow myopia progression in children aged 8-12 at the initiation of treatment.^{†1} It has been clinically shown to reduce myopia progression by half on average for age-appropriate children wearing these contact lenses as prescribed.*^{‡‡‡‡‡‡3,46} Additionally, it boasts a strong safety profile as a 1-day lens,²⁷ and is backed by 7 years of international clinical research confirming its effectiveness in children aged 8-12 at initiation of treatment.^{†5,6}

Convenience and Comfort



Designed as daily disposable contact lenses, MiSight® 1 day lenses are convenient and comfortable for both age-appropriate children and parents.^{1,31,47} There is no need for cleaning or storage, making it easy to use and suitable for active lifestyles.

*Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

†Compared to a single vision 1 day lens over a 3 year period.

‡ Preliminary international study data shows that, on average, for children that discontinued treatment at age 14-19 following 3 or 6 years of MiSight® 1 day wear, the eye growth reverted to age-expected average myopic progression rates. Disclaimer: The stability of the myopia reduction effect 1-year post-treatment is being further evaluated in a post-approval study in the U.S. as a condition of FDA approval for MiSight 1 day.

‡‡‡‡‡‡ Using measured and modeled data, pooled across ages (8-17), MiSight® 1 day slowed myopia progression by an average of approximately 50%.

‡‡‡ Myopic children fit with MiSight® 1 day contact lenses ages 8-15 continued to experience slowed myopia progression as long as they remained wearing the lenses as prescribed.

Summary of clinical recommendations



1. RECEIVING YOUR EYE DROPS

- A prescription will be sent by your doctor to ImprimisRx Pharmacy
- Contact them directly and they will ship your supply directly to your house
- ImprimisRx Pharmacy contact information
 - Phone: 1-844-446-6979
 - Website: www.imprimisrx.com

2. DOSING REGIMEN

- Instill 1 drop into each of your child's eyes every night before bed
- For atropine to be effective, it is important the drops are getting into the eyes and are being used daily



3. ATROPINE AND VISION CORRECTION

- Atropine works to slow the progression of myopia, but does not provide any vision correction
- It is important to make sure your child wears their prescribed glasses or contact lenses to provide clear vision while using atropine

4. TREATMENT DURATION

- Atropine is generally used until the age of around 16
- Your doctor will monitor for a period of stability and find the right time to discontinue treatment
- Close monitoring after discontinuation of atropine is necessary to ensure minimal progression



5. TREATMENT DISCONTINUATION

- When the time comes to stop atropine, your doctor will provide discontinuation instructions
- Lowering the frequency or concentration of atropine will ensure a safe and effective cessation of treatment

Myopia Management: Initial Enrollment

Evidence in scientific literature suggests that some novel spectacles, contact lenses, and eye drops may slow the progression of nearsightedness in children. Hillsboro Vision Clinic offers three ways to potentially slow the progression of nearsightedness in children: Stellest Spectacle Lenses, Misight contact lenses, and low dose atropine eye drops.

Enrolling in HVC’s myopia management program is \$300 per year and is paid at the start of treatment. Renewal is \$200 and will be paid 1 time per year at each comprehensive vision exam until the completion of treatment. This includes all the follow-up appointments and additional testing needed throughout the year; additional costs will apply based on the chosen treatment modality.

Treatment Modality

- Stellest Spectacle Lenses

- Misight Contact Lenses

- Atropine Eye Drops

I understand the risks as explained by my Optometrist and indicated above, and I understand that while these treatments have research backing their safety and efficacy, there is no guarantee or assurance of any treatment outcome for my child.

Child’s name (print): _____

Parent’s name (sign): _____

Date: _____

Staff Attestation: _____

Myopia Management: Renewal

Evidence in scientific literature suggests that some novel spectacles, contact lenses, and eye drops may slow the progression of nearsightedness in children. Hillsboro Vision Clinic offers three ways to potentially slow the progression of nearsightedness in children: Stellest Spectacle Lenses, Misight daily soft contact lenses, and low dose atropine eye drops.

Renewal for treatment year 2 and beyond is \$200 and will be paid 1 time per year at each comprehensive vision exam until the completion of treatment. This includes all the follow-up appointments and additional testing needed throughout the year; additional costs will apply based on the chosen treatment modality.

Treatment Modality

- o Stellest Spectacle Lenses
- o Misight Contact Lenses
- o Atropine Eye Drops

I understand the risks as explained by my Optometrist and indicated above, and I understand that while these treatments have research backing their safety and efficacy, there is no guarantee or assurance of any treatment outcome for my child.

Child's name (print): _____

Parent's name (sign): _____

Date: _____

Staff Attestation: _____